menu search

NVO / Why Novo Nordisk Stock Flopped on Friday

Why Novo Nordisk Stock Flopped on Friday
An analyst's price target bump was overshadowed by an insider's stock sale. Both were relatively small-scale events. Read More
Posted: Nov 3 2023, 17:14
Author Name: The Motley Fool
Views: 071882

NVO News  

Why Novo Nordisk Stock Flopped on Friday

By The Motley Fool
November 3, 2023

Why Novo Nordisk Stock Flopped on Friday

An analyst's price target bump was overshadowed by an insider's stock sale. Both were relatively small-scale events. more_horizontal

Novo Nordisk to release clinical update on star drug Wegovy

By Proactive Investors
November 3, 2023

Novo Nordisk to release clinical update on star drug Wegovy

Novo Nordisk (NYSE:NVO) remains firmly in favour with analysts at Barclays ahead of the latest trial data for diabetes drug Wegovy that is due next we more_horizontal

Weight loss drug Wegovy sales fuel Novo Nordisk stock performance

By Yahoo Finance
November 2, 2023

Weight loss drug Wegovy sales fuel Novo Nordisk stock performance

Novo Nordisk (NVO) stock rose after the pharmaceutical company reported strong third-quarter sales growth, fueled by its popular weight-loss drug, Weg more_horizontal

Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month

By Reuters
November 2, 2023

Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month

The majority of U.S. patients with health insurance coverage taking Novo Nordisk's powerful weight-loss drug Wegovy are paying less than $25 per month more_horizontal

US Wegovy Supply to Expand ‘Gradually': Novo Nordisk CEO

By Bloomberg Markets and Finance
November 2, 2023

US Wegovy Supply to Expand ‘Gradually': Novo Nordisk CEO

Novo Nordisk CEO Lars Fruergaard Jorgensen says starter doses of the company's weight loss medications will “be lowered somewhat” through the end more_horizontal

Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says

By CNBC
November 2, 2023

Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says

Novo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months more_horizontal

Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic

By Reuters
November 2, 2023

Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic

Novo Nordisk is ramping up its in-house manufacturing capacity to fill injection pens for its diabetes drug Ozempic and for the European version of it more_horizontal

Novo Nordisk: obesity drugs priority over century-old focus on insulin

By Reuters
November 2, 2023

Novo Nordisk: obesity drugs priority over century-old focus on insulin

Novo Nordisk said on Thursday treating obesity with its weight-loss drug Wegovy as a precursor to type 2 diabetes was a priority for the company, cont more_horizontal


Search within

Pages Search Results: